Companion Diagnostics Forum 2011
April 27 - 29, 2011
Philadelphia PA , USA
IQPC’s Companion Diagnostic Forum will take an in-depth look at challenges with implementing drug-diagnostic co-development, regulatory hurdles to overcome, best practices in the diagnostics field and approaches for handling drug response variability for clinical and commercial success. Join us in Philadelphia April 27-29, 2011 to hear from industry experts on how to improve your methods as well as gain crucial insight into the companion diagnostic field.
Companion diagnostic co-development has the potential to significantly alter the drug development process and commercialization of drug candidates by yielding safer drugs with enhanced therapeutic efficacy in a faster, more cost-effective manner. This can be done by providing drug developers information on how a drug works in the body, before clinical signs and symptoms are evaluated in patients through trials. Since biomarkers need to be qualified in the context of their intended use, using them as part of the clinical trial process will provide evidence of the marker’s clinical utility and the value of the diagnostic test. Companion diagnostics represents a big near term opportunity for drug developers to seize. The benefits of getting the right drug to the right patient by tailoring treatments to selected patient groups defined by biomarkers are huge.
* Identifying robust biomarkers for drug and diagnostic co-development
* Addressing the regulatory viability of companion diagnostics
* Using Next Generation sequencing in preclinical models
* Issues with ROI and expectations of future reimbursement models
* Investigating different methods for developing a drug with a diagnostic
Companion diagnostic co-development has the potential to significantly alter the drug development process and commercialization of drug candidates by yielding safer drugs with enhanced therapeutic efficacy in a faster, more cost-effective manner. This can be done by providing drug developers information on how a drug works in the body, before clinical signs and symptoms are evaluated in patients through trials. Since biomarkers need to be qualified in the context of their intended use, using them as part of the clinical trial process will provide evidence of the marker’s clinical utility and the value of the diagnostic test. Companion diagnostics represents a big near term opportunity for drug developers to seize. The benefits of getting the right drug to the right patient by tailoring treatments to selected patient groups defined by biomarkers are huge.
* Identifying robust biomarkers for drug and diagnostic co-development
* Addressing the regulatory viability of companion diagnostics
* Using Next Generation sequencing in preclinical models
* Issues with ROI and expectations of future reimbursement models
* Investigating different methods for developing a drug with a diagnostic
Related events
Companion Diagnostics Forum April 27 - 29, 2011
